In JPM interview, Gottlieb outlines FDA efforts to promote biopharma competition
The agency plans to release several guidances on complex generics and biosimilars, along with taking a deep dive into the Orange Book patent and exclusivity database.
Key takeaways from the J.P. Morgan Healthcare Conference
The J.P. Morgan Healthcare Conference is over and there are lessons to be learned about investors, the future of AI, diversity in healthcare, and the unexpected generosity of strangers.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Looking to approach biotech investors? Here’s what you should know
Biotech insiders at a panel discussion shared tidbits of information that reveals a lot about the investment landscape in biotech and pharma.
At JPM, Medtronic CEO talks value-based care, pushes back on criticism of M&A strategy
Omar Ishrak highlights a few products with which Medtronic hopes to succeed in value-based care and responds to criticism about how it approaches high-growth companies from an acquisitions.
How to woo investors at #JPM18: Stick a needle in their arm
San Diego, California-based Genalyte has spent 10 years developing its lab-on-a-chip technology. Now it’s ready, to try it out on J.P. Morgan investors, quite literally.
Does the J.P. Morgan Healthcare Conference really set the tone for year ahead for biopharma?
The J.P. Morgan Healthcare Conference is about so much more than the company presentations. Partnerships are made, deals are signed, and the tone for the biopharma year ahead is set. Or is it?
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
How women are fighting to be part of the new world order in healthcare, life sciences and beyond
Even at the J.P. Morgan Healthcare Conference, the tide seems to have turned. This year, there were at least eight events that I personally heard of that were women-only and overflowing.
Valeant to pay down debt with $2.12B in asset sales
Valeant was the talk of the town (or at least Union Square) on day two of the J.P. Morgan Healthcare Conference, announcing two divestitures worth $2.12 billion and unveiling a plan to pay down $5 billion in debt over the next 18 months.
7 insider tricks GE Ventures uses to scale its portfolio companies
Only one in 500 new businesses in the United States will reach at least $100 million in revenue, and only one in 17,000 will see $500 million in revenue.
Two charts capture the dark mood around Big Pharma in 2017
At a breakfast reception during the ongoing J.P. Morgan Healthcare Conference, the mood around the prospects for Big Pharma in 2017 was downright gloomy.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Joe Biden: What the hell are we doing?
In San Francisco during J.P. Morgan week, the vice president called for the end to a siloed healthcare system to help accelerate the battle against cancer and announced what he will do after his tenure in public office ends.
LifeSci Advisors in damage control, now formally promoting gender equality
In a statement, LifeSci Advisors says it "is dedicated to transforming itself into a model for promoting gender diversity" in the industry.
LifeSci Advisors apologizes formally for J.P. Morgan cocktail model incident
LifeSci Advisors has formally apologized for hiring cocktail models at this year's J.P. Morgan healthcare conference, and has committed to "launching a series of concrete initiatives to address these systemic issues."
The man athenahealth’s CEO tried to save at J.P. Morgan Healthcare conference died
The Office of the Chief Medical Examiner declined to give a cause of death pending the outcome of additional tests.
Meaningful use… and more J.P. Morgan: 5 must-read stories from MedCity News this week
Also, we talk Meaningful Use and about the New England Journal of Medicine's opinion that we should pursue a "patient-driven health information economy"